We can evaluate it
For questions regarding the offering or assistance in quoting Medical for the Highmark Southeastern PA regions, please reach out to your NFP BNGA Team via [email protected]
These compounds interact with receptors on L-cells, signaling them to release GLP-1
Positive lipid outcomes have been demonstrated in several of the critical trials that established the cardiovascular benefits of tirzepatide and semaglutide (Table 1
Rosenstock J, Raccah D, Koranyi L, et al
While nausea, vomiting, and diarrhea are the most commonly reported gastrointestinal adverse effects with GLP-1-based therapies (occurring in 15-40% of patients depending on the agent and dose), FDA prescribing information for several of these medications does list dyspepsia (indigestion) and, in some cases, gastroesophageal reflux disease (GERD) as reported adverse reactions